Trial Profile
TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma - A Phase Ib Clinical Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary) ; Infliximab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- Acronyms TICIMEL
- 11 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Results of final analysis safety and activity at a follow-up of over 20 months presented at the 47th European Society for Medical Oncology Congress
- 08 Nov 2021 Planned End Date changed from 1 Apr 2023 to 1 Nov 2023.